Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 18/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 7/20 | 0.41 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.41 |
| ▸ | IDO1 | P14902 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26072684 | 1.00 | PTGS2 (0.41) | PTGS2PTGS1HSD11B1IDO1 | |
| SCHEMBL26072918 | 0.88 | PTGS2 (0.42) | PTGS2PTGS1HSD11B1IDO1 | |
| SCHEMBL26072738 | 0.84 | KCNH2 (0.34) | PTGS2 | |
| SCHEMBL26072702 | 0.84 | PTGS2 (0.40) | PTGS2PTGS1HSD11B1IDO1 | |
| SCHEMBL26072089 | 0.83 | PTGS2 (0.40) | PTGS2PTGS1IDO1 | |
| SCHEMBL26072059 | 0.83 | KDM5A (0.39) | PTGS2PTGS1HSD11B1IDO1 | |
| SCHEMBL26072604 | 0.83 | PTGS2 (0.39) | PTGS2PTGS1HSD11B1IDO1 | |
| SCHEMBL26072721 | 0.82 | PTGS2 (0.47) | PTGS2PTGS1IDO1 | |
| SCHEMBL26072708 | 0.82 | PTGS2 (0.38) | PTGS2PTGS1HSD11B1IDO1 | |
| SCHEMBL26072322 | 0.81 | KDM4E (0.41) | PTGS2PTGS1HSD11B1IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4200298-A1 | 1H-PYRROLO[3,2-C]PYRIDINE AND 1H-PYRROLO[2,3-C]PYRIDINE DERIVATIVES AS TLR9 INHIBITORS FOR THE TREATMENT OF FIBROSIS | Bristol-Myers Squibb Company (US) | 2023-06-28 | — | — | EP | disclosed |
| WO-2022040267-A1 | 1H-PYRROLO[3,2-C]PYRIDINE AND 1H-PYRROLO[2,3-C]PYRIDINE DERIVATIVES AS TLR9 INHIBITORS FOR THE TREATMENT OF FIBROSIS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-02-24 | — | — | WO | disclosed |